Efficacy and safety of concentration-controlled everolimus with reduced-dose cyclosporine in Japanese de novo renal transplant patients: 12-month results

Transplantation Research

Volumn 2, Issue 1, 2013, Pages

  Takahashi, Kota ^a   Uchida, Kazuharu ^b   Yoshimura, Norio ^c   Takahara, Shiro ^d   Teraoka, Satoshi ^e   Teshima, Rie ^f   Cornu Artis, Catherine ^g   Kobayashi, Eiji ^h  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b AICHI MEDICAL UNIVERSITY   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e International University of Health and Welfare   (Japan)

^f NOVARTIS PHARMA K K   (Japan)

^g NOVARTIS PHARMA AG   (Switzerland)

^h JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Cyclosporine; Everolimus; Renal function; Renal transplantation; Therapeutic drug monitoring

Indexed keywords

BASILIXIMAB; CHOLESTEROL; CORTICOSTEROID; CYCLOSPORIN; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TRIACYLGLYCEROL;

ACNE; ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BLOOD PRESSURE; CONSTIPATION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; EDEMA; ELECTROLYTE DISTURBANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; FLOW CYTOMETRY; FOLLOW UP; GASTROENTERITIS; GLOMERULUS FILTRATION RATE; HERPES ZOSTER; HIRSUTISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LYMPHOCELE; MAJOR CLINICAL STUDY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; MULTICENTER STUDY; NEPHROTOXICITY; NEUTROPENIA; OPEN STUDY; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; UNSPECIFIED SIDE EFFECT;

EID: 84897427477     PISSN: None     EISSN: 20471440     Source Type: Journal    
DOI: 10.1186/2047-1440-2-14     Document Type: Article

References (25)

1. The Japanese Society for Clinical Renal Transplantation Annual progress report from the Japanese renal transplant registry: number of renal transplantations in 2008, part 2. ISYOKU 2009, 44:548. The Japanese Society for Clinical Renal Transplantation.
2. Golshayan D, Pascual M. Minimization of calcineurin inhibitors to improve long-term outcomes in kidney transplantation. Transpl Immunol 2008, 20:21. 10.1016/j.trim.2008.08.006, 18775494.
3. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003, 349:2326. 10.1056/NEJMoa020009, 14668458.
4. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004, 78:557.
5. Schuler W, Sedrani R, Cottens S, Häberlin B, Schulz M, Schuurman HJ, Zenke G, Zerwes HG, Schreier MH. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997, 64:36. 10.1097/00007890-199707150-00008, 9233698.
6. Tedesco-Silva H, Vitko S, Pascual J, Eris J, Magee JC, Whelchel J, Civati G, Campbell S, Alves-Filho G, Bourbigot B, Garcia VD, Leone J, Esmeraldo R, Rigotti P, Cambi V. Haas T; 2306 and 2307 Study Groups: 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Transpl Int 2007, 20:27. 10.1111/j.1432-2277.2006.00414.x, 17181650.
7. Lorber MI, Mulgaonkar S, Butt KM, Elkhammas E, Mendez R, Rajagopalan PR, Kahan B, Sollinger H, Li Y, Cretin N. Tedesco H; B251 Study Group: Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 2005, 80:244. 10.1097/01.TP.0000164352.65613.24, 16041270.
8. Vitko S, Tedesco H, Eris J, Pascual J, Whelchel J, Magee JC, Campbell S, Civati G, Bourbigot B, Alves Filho G, Leone J, Garcia VD, Rigotti P, Esmeraldo R, Cambi V, Haas T, Jappe A, Bernhardt P, Geissler J, Cretin N. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004, 4:626. 10.1111/j.1600-6143.2004.00389.x, 15023156.
9. Vitko S, Margreiter R, Weimar W, Dantal J, Kuypers D, Winkler M, Oyen O, Viljoen HG, Filiptsev P, Sadek S, Li Y, Cretin N, Budde K. RAD B201 Study Group: Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005, 5:2521. 10.1111/j.1600-6143.2005.01063.x, 16162203.
10. Nashan B, Curtis J, Ponticelli C, Mourad G, Jaffe J, Haas T. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study. Transplantation 2004, 78:1332. 10.1097/01.TP.0000140486.97461.49, 15548972.
11. Chan L, Greenstein S, Hardy MA, Hartmann E, Bunnapradist S, Cibrik D, Shaw LM, Munir L, Ulbricht B, Cooper M. CRADUS09 Study Group: Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation 2008, 85:821. 10.1097/TP.0b013e318166927b, 18360262.
12. Tedesco-Silva H, Cibrik D, Johnston T, Lackova E, Mange K, Panis C, Walker R, Wang Z, Zibari G, Kim YS. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant 2010, 10:1401. 10.1111/j.1600-6143.2010.03129.x, 20455882.
13. Dantal J, Francois Berthoux F, Moal M-C, Rostaing L, Legendre C, Genin R, Toupance O, Moulin B, Merville P, Rerolle JP, Bayle F, Westeel PF, Glotz D, Kossari N, Lefrançois N, Charpentier B, Quéré S, Di Giambattista F, Cassuto E. RAD A2420 Study Group: Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. Transpl Int 2010, 23:1084. 10.1111/j.1432-2277.2010.01094.x, 20500493.
14. Salvadori M, Scolari MP, Bertoni E, Citterio F, Rigotti P, Cossu M, Dal Canton A, Tisone G, Albertazzi A, Pisani F, Gubbiotti G, Piredda G, Busnach G, Sparacino V, Goepel V, Messa P, Berloco P, Montanaro D, Veroux P, Federico S, Bartezaghi M, Corbetta G, Ponticelli C. Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: a multicenter, randomized, controlled trial. Transplantation 2009, 88:1194. 10.1097/TP.0b013e3181bb43ec, 19935373.
15. Vitko S, Margreiter R, Weimar W, Dantal J, Viljoen HG, Li Y, Jappe A, Cretin N. RAD B201 Study Group: Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 2004, 78:1532. 10.1097/01.TP.0000141094.34903.54, 15599319.
16. Japanese package insert of Certican tablet [http://www.info.pmda.go.jp/downfiles/ph/PDF/300242_3999022F1028_1_08.pdf], Japanese package insert of Certican tablet.
17. Basic Principles on Global Clinical Trials Pharmaceuticals and Medical Devices Agency (PMDA Notification No. 0928010) [http://www.pmda.go.jp/english/service/pdf/notifications/PFSB-ELD-0928010.pdf], Basic Principles on Global Clinical Trials.
18. Racusen LC, Colvin RB, Solez K, Mihatsch MJ, Halloran PF, Campbell PM, Cecka MJ, Cosyns JP, Demetris AJ, Fishbein MC, Fogo A, Furness P, Gibson IW, Glotz D, Hayry P, Hunsickern L, Kashgarian M, Kerman R, Magil AJ, Montgomery R, Morozumi K, Nickeleit V, Randhawa P, Regele H, Seron D, Seshan S, Sund S, Trpkov K. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003, 3:708. 10.1034/j.1600-6143.2003.00072.x, 12780562.
19. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003, 41:1.
20. Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002, 62:311. 10.1046/j.1523-1755.2002.00424.x, 12081593.
21. Morozumi K, Thiel G, Albert FW, Banfi G, Gudat F, Mihatsch MJ. Studies on morphological outcome of cyclosporine-associated arteriolopathy after discontinuation of cyclosporine in renal allografts. Clin Nephrol 1992, 38:1-8.
22. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004, 78:557-565.
23. Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, Larsen CP, Ahmed R. mTOR regulates memory CD8 T-cell differentiation. Nature 2009, 460:108. 10.1038/nature08155, 2710807, 19543266.
24. Turner AP, Shaffer VO, Araki K, Martens C, Turner PL, Gangappa S, Ford ML, Ahmed R, Kirk AD, Larsen CP. Sirolimus enhances the magnitude and quality of viral-specific CD8(+) T-cell responses to vaccinia virus vaccination in rhesus macaques. Am J Transplant 2011, 11:613. 10.1111/j.1600-6143.2010.03407.x, 3076606, 21342450.
25. Saemann MD, Haidinger M, Hecking M, Hörl WH, Weichhart T. The multifunctional role of mTOR in innate immunity: implications for transplant immunity. Am J Transplant 2009, 9:2655. 10.1111/j.1600-6143.2009.02832.x, 19788500.